読み込み中
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
前日終値
$24.37
+$0.34 · +1.41%
日中の時刻はETです。市場データは遅延する場合があります。
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
日中レンジ
現在 $24.37
52週レンジ
現在 $24.37
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
61
強気
リスク
45
やや高いリスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
日中レンジ
現在 $24.37
52週レンジ
現在 $24.37
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | — | 21万 USD |
| 売上原価 | 66.1万 USD | 50.2万 USD | — | 34.2万 USD | 14.5万 USD |
| 粗利益 | −66.1万 USD | −50.2万 USD | — | −34.2万 USD | 6.5万 USD |
| 研究開発 | 4561.9万 USD | 4699.6万 USD | 3029.1万 USD | 2368.8万 USD | 837万 USD |
| 販売・一般管理 | 2074.5万 USD | 2161.4万 USD | 751.8万 USD | 516.2万 USD | 375.1万 USD |
| 営業費用 | 6570.3万 USD | 6810.8万 USD | 3780.9万 USD | 2885万 USD | 1212.1万 USD |
| 受取利息 | 660.3万 USD | 885.1万 USD | 234.9万 USD | 11.4万 USD | 2000 USD |
| 支払利息 | 246.9万 USD | −137.5万 USD | 137万 USD | — | — |
| 減価償却費と償却費 | 66.1万 USD | 50.2万 USD | 37.3万 USD | 34.2万 USD | 14.5万 USD |
| 営業利益 | −6636.4万 USD | −6861万 USD | −3780.9万 USD | −2919.2万 USD | −1205.6万 USD |
| 純利益 | −6323.8万 USD | −6143.1万 USD | −3630.5万 USD | −2771万 USD | −918.7万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$38.00
上昇余地（55.93%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3580.03万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2043.91万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1239.22万0.01%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO707.67万0.05%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB666.82万0.06%108.2億 USD0.44%$206.49+3.00%
State Street SPDR S&P Pharmaceuticals ETFXPH546.77万1.18%4.62億 USD0.35%$64.65+1.60%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS536.37万1.34%3.99億 USD0.60%$107.24+1.40%
Vanguard Russell 2000 ETFVTWO532.48万0.03%180億 USD0.06%$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBState Street SPDR S&P Pharmaceuticals ETFXPHInvesco Dorsey Wright SmallCap Momentum ETFDWASVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
